Maco Pharma developped the FIRST virally inactivated human platelet lysate on the market, MultiPL’i
The amplification of stem cells in defined, standardised, xeno-free conditions represents a major challenge for the production of safe and reproducible cell therapy products . Furthermore, the regulatory environment is on constant evolution, for that reason Maco Pharma developed the first VIRALLY INACTIVATED human platelet lysate: MultiPL’i that meets the requirements of adventitious agent transmission reduction (General Chapter 5.2.12 of the European Pharmacopeia current version).
An efficient, standardized and safer* supplement to expand multiple cell types.
MultiPL’i is an efficient, standardized and safer* alternative to the FBS. As efficient and standardized as their predecessors MultiPL’ and safer* thanks to the pathogen reduction step. MultiPL’i is available in 2 distincts compositions MultiPL’30i and MultiPL’100i.
MultiPL’i benefits compared to FBS:
- Xenogenic risk free
- Enhanced cell growth kinetics and reduced supplementation
- Cost consistency and pricing stability thanks to large batches manufacturing
- Reduced cell culture cost by increasing amplification yield with less supplementation in less time
- Qualified human blood donation with virus testing and pathogen reduction ensure safety
1. Performance
* Than their predecessors MultiPL’30 and MultiPL’100.